Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hanzhou, Zhejiang

Zhejiang Cancer Hospital, Hanzhou, Zhejiang

Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang